General Information of Drug (ID: DMJUV6C)

Drug Name
BMS-223131 Drug Info
Synonyms 4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
Indication
Disease Entry ICD 11 Status REF
Erectile dysfunction HA01.1 Phase 2 [1]
Cross-matching ID
PubChem CID
9951995
CAS Number
CAS 275375-69-4
TTD Drug ID
DMJUV6C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NS-1619 DMES0OT Asthma CA23 Terminated [2]
CNS-1237 DMP3QAZ Cerebrovascular ischaemia 8B1Z Terminated [3]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [4]
iberiotoxin DMRIG3O Discovery agent N.A. Investigative [4]
paxilline DMPF2N1 Discovery agent N.A. Investigative [5]
slotoxin DMBD6TC Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Charybdotoxin receptor beta-4 (BKbeta4) TT1AQ50 KCMB4_HUMAN Modulator [1]

References

1 Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7.
2 BK channel activation by NS-1619 is partially mediated by intracellular Ca2+ release in smooth muscle cells of porcine coronary artery
3 Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380).
5 Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8.
6 Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett. 2001 Sep 21;505(3):369-73.